Stratos Medical
Developer of an investigational indwelling vascular access system intended to replace routine dialysis needle cannulation for arteriovenous fistula (AVF) access. The company is focused on device design and clinical development to enable pain‑free repeat access, support self‑cannulation for home hemodialysis, and reduce AVF needle‑related complications. Headquartered in Galway, Ireland, with R&D centres in Ireland and South Africa and an additional presence in Maine, USA.
Industries
Nr. of Employees
small (1-50)
Stratos Medical
Unit 102, ATU iHub, Dublin Road, Galway, H91 DCH9, Ireland
Patents
Products
TrackSmart
Investigational indwelling AVF repeat-access system comprising a pair of hub-and-port devices affixed to the arm and single-use blunt cannulas that are advanced through the hubs to access the fistula; devices are designed to be replaced every 28 days.
TrackSmart
Investigational indwelling AVF repeat-access system comprising a pair of hub-and-port devices affixed to the arm and single-use blunt cannulas that are advanced through the hubs to access the fistula; devices are designed to be replaced every 28 days.
Services
Collaborative development with clinicians and dialysis providers to refine device placement procedures and clinical workflows.
Partnership and stakeholder engagement to pilot and enable workflows that support patient self-cannulation and home-based treatment.
Collaborative development with clinicians and dialysis providers to refine device placement procedures and clinical workflows.
Partnership and stakeholder engagement to pilot and enable workflows that support patient self-cannulation and home-based treatment.
Expertise Areas
- Vascular access medical device development
- Clinical procedure design for vascular access placement
- Home hemodialysis enablement and self-cannulation workflows
- Infection control for indwelling vascular devices
Key Technologies
- Hub-and-port indwelling vascular access systems
- Blunt cannula access for hemodialysis
- Percutaneous placement using Huber-tip placement needles
- Skin-contact biocompatible materials
News & Updates
The investigational device development has received financial support from public and venture funding organisations to advance R&D and testing.
Company indicates the investigational device is expected to be available in 2026 pending rigorous testing and regulatory approvals.
The investigational device development has received financial support from public and venture funding organisations to advance R&D and testing.
Company indicates the investigational device is expected to be available in 2026 pending rigorous testing and regulatory approvals.